Visualize the benefits. Experience the difference.
The only dispersive OVD in the US with the free radical protection of sorbitol.1,2
As the only dispersive OVD in the U.S. formulated with the free radical suppression properties of sorbitol, ClearVisc provides a dual-action system that delivers both physical and chemical protection during cataract procedures.1,2
Sign up for your ClearVisc TrialTWO-WAY PROTECTION
With the free radical-inhibiting power of sorbitol, ClearVisc’s dual-action system delivers physical and chemical protection during cataract procedures.
FREE RADICALS IN CATARACT SURGERY
Free radicals form in the eye as a result of chemical reactions caused during cataract procedures. They can contribute to corneal damage and possible decompensation, which can lead to post-surgical complications such as a cloudy cornea.
ClearVisc™ with sorbitol chemically bonds to free radical particles to deliver a high level of free radical scavenging activity.1,2
Sorbitol chemical compound
Sorbitol + free radicals in the eye
Sorbitol neutralizing free radicals
PRESERVE THE TISSUES. PROTECT THE OUTCOMES.1
ClearVisc with sorbitol was shown in an in-vitro study to deliver significantly higher free radical inhibition than other viscoelastic formulation(s).2
CLEAR ADVANTAGE
“It’s clear, so it doesn’t impair visibility in the eye…It didn’t impair my ability to see things more efficiently while operating.”
Mitchell A. Jackson, MD Investigator in ClearVisc FDA Trial
Tissue Visibility
POST-OP CLARITY
In a survey, ClearVisc was ranked by surgeons as having exceptional tissue visibility compared to other OVDs.1 *
Clinical Outcomes
91%
Clinically clear corneas at 1-day post-operative.1
100%
Clinically clear corneas at 1-week post-operative.1
LARGER FILL VOLUME
ClearVisc™ is supplied in a 1.0 mL syringe, reducing the need to open a second pack mid-procedure.
- Data on File. Bausch & Lomb Incorporated, 2021.
- Francesco Maugeri, Adriana Maltese, Keith W. Ward & Claudio Bucolo (2007). Hydroxyl Radical Scavenging Activity of a New Ophthalmic Viscosurgical Device, Current Eye Research, 32:2, 105-111, DOI:10.1080/02713680601147716.
